Nine genotyped cutaneous AJCC Stage III early passage melanoma cell lines were selected which broadly represents common clinically relevant mutations in the MAPK pathway (Supplementary Table 1).24 Three cell lines possessed an activating NRAS mutation (Q61K/L) (C002, C054, and C096), three possessed BRAF V600E/K mutations (C078, C088, and C045), and three cell lines were wild type for BRAF and NRAS (C037, C052, and C084). Here, NRAS is linked to melanoma.